SING GEORGE L 4
4 · REGENERON PHARMACEUTICALS, INC. · Filed Jan 3, 2025
Insider Transaction Report
Form 4
SING GEORGE L
Director
Transactions
- Exercise/Conversion
Common Stock
2024-12-31$413.33/sh+3,338$1,379,696→ 29,610 total - Tax Payment
Common Stock
2024-12-31$708.19/sh−1,948$1,379,554→ 27,662 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-12-31−3,338→ 0 totalExercise: $413.33Exp: 2025-01-02→ Common Stock (3,338 underlying) - Award
Non-Qualified Stock Option (right to buy)
2025-01-02+1,958→ 1,958 totalExercise: $719.37Exp: 2035-01-02→ Common Stock (1,958 underlying) - Award
Common Stock
2025-01-02+166→ 27,828 total
Holdings
- 750(indirect: By Spouse)
Common Stock
- 1,000(indirect: By Trust)
Common Stock
- 400(indirect: By Spouse)
Common Stock
Footnotes (3)
- [F1]Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
- [F2]The stock option vested in three equal annual installments, commencing one year after the date of grant.
- [F3]On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.